50817-80-6

Basic information

• Product Name: 2-Chloro-4-methylbenzaldehyde
• Synonyms: 2-CHLORO-4-METHYLBENZALDEHYDE;3-Chloro-4-formyltoluene, 2-Chloro-p-tolualdehyde;2-Chloro-p-tolualdehyde;Benzaldehyde,2-chloro-4-methyl-
• CAS NO: 50817-80-6
• Molecular Formula: C₈H₇ClO
• Molecular Weight: 154.59
• Product Categories: Aldehydes;Phenyls & Phenyl-Het
• Mol File: 50817-80-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 27-30°C
• Boiling Point: 234.7 °C at 760 mmHg
• Flash Point: 105.8 °C
• Appearance: /
• Density: 1.195 g/cm³
• Vapor Pressure: 0.0521mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloro-4-methylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-methylbenzaldehyde(50817-80-6)
• EPA Substance Registry System: 2-Chloro-4-methylbenzaldehyde(50817-80-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41-51
• Safety Statements: 26-39-45
• WGK Germany: 3
• Hazardous Substances Data: 50817-80-6(Hazardous Substances Data)

Usage

General Description

2-Chloro-4-methylbenzaldehyde, also known as p-chloro-p-tolualdehyde, is a chemical compound with the molecular formula C8H7ClO. This colorless to pale yellow liquid is commonly used in the production of pharmaceuticals and dyes. It is also used as a starting material for the synthesis of various organic compounds. 2-Chloro-4-methylbenzaldehyde is a versatile intermediate in organic synthesis due to its reactivity and ability to undergo various chemical reactions, such as substitution and oxidation. It is important to handle this chemical with care, as it may cause irritation to the skin, eyes, and respiratory system. Additionally, proper safety measures must be followed during its storage and handling.

InChI:InChI=1/C8H7ClO/c1-6-2-3-7(5-10)8(9)4-6/h2-5H,1H3

Upstream product

• 201230-82-2 carbon monoxide 
• 108-41-8 1-chloro-3-methylbenzene 
• 39652-31-8 (2-chloro-4-methylphenyl)methanol 
• 6627-51-6 1-bromo-2-chloro-4-methylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 50-00-0 formaldehyd 
• 615-65-6 2-chloro-4-methyl-benzenamine 
• 141-79-7 4-methyl-pent-3-en-2-one 

Downstream Products

• 99725-42-5 N-<(2-chloro-4-methylphenyl)methylene>benzamine 
• 755025-50-4 (E)-3-(2-Chloro-4-methyl-phenyl)-1-naphthalen-2-yl-propenone 
• 1241405-36-6 methyl 1-[3-chloro-4-(1-methoxy-1-oxopropan-2-yl)-benzyl]-2-oxocyclopentanecarboxylate 
• 1313592-02-7 sodium 2-{2-chloro-4-[(2-oxocyclopentyl)methyl]-phenyl}propanoate 
• 1241405-23-1 C₉H₉ClO 
• 871477-05-3 C₁₀H₁₁ClO₂ 
• 1241405-32-2 C₁₁H₁₂BrClO₂ 
• 1241405-28-6 methyl 2-(2-chloro-4-methylphenyl)propanoate 
• 2043-83-6 2-chloro-4-methylphenylacetic acid 
• 1613641-70-5 3-(2-chloro-4-methylphenyl)-2-methylpropanoyl chloride 
• 1506521-66-9 C₁₁H₁₃ClO₂ 
• 39652-31-8 (2-chloro-4-methylphenyl)methanol 
• 2719-39-3 2-chloro-1-(chloromethyl)-4-methylbenzene 

Relevant articles and documents

CATALYSTS

A complex of formula (I) wherein M is zirconium or hafnium; each X independently is a sigma ligand; L is a divalent bridge selected from -R'2C-, -R'2C-CR'2-, -R'2Si-, -R'2Si-SiR'2-, -R'2Ge-, wherein each R' is independently a hydrogen atom or a C1-C20-hydrocarbyl group optionally containing one or more silicon atoms or heteroatoms of Group 14-16 of the periodic table or fluorine atoms, and optionally two R' groups taken together can form a ring; R2 and R2' are each independently a C1-C20 hydrocarbyl group, -OC1- hydrocarbyl group or -SC1-20 hydrocarbyl group; R5 is a -OC1-20 hydrocarbyl group or -SC1-20 hydrocarbyl group, said R5 group being optionally substituted by one or more halo groups; R5' is hydrogen or a C1-20 hydrocarbyl group; -OC1-20 hydrocarbyl group or -SC1-20 hydrocarbyl group; said C1-20 hydrocarbyl group being optionally substituted by one or more halo groups; R6 and R6' are each independently a C1-20 hydrocarbyl group; -OC1-20 hydrocarbyl group or -SC1-20 hydrocarbyl group; each R1 and R1' are independently -CH2Rx wherein Rx are each independently H, or a C1-20 hydrocarbyl group, optionally containing heteroatoms.

CATALYST

A catalyst in solid particulate form free from an external carrier material comprising (i) a complex of formula (I) wherein M is zirconium or hafnium; each X is a sigma ligand; L is a divalent bridge selected from -R'2C-, -R'2C-CR'2-, -R'2Si-, -R'2Si-Si R'2-, -R'2 Ge-, wherein each R' is independently a hydrogen atom, C1-20-alkyl, tri(C1-20-alkyl)silyl, C6-20-aryl, C7-20-arylalkyl or C7-20-alkylaryl; R2 is a C1-20-hydrocarbyl radical; R2' is a C1-20-hydrocarbyl radical;R6 is a linear or branched aliphatic C1-20-hydrocarbyl group, SR9or OSR9;R6' is a linear or branched aliphatic C1-20-hydrocarbyl group, SR9'or OR9'; with the proviso that neither R6 or R6' represents a group having a quaternary carbon atom directly attached to the indenyl ring; R9 is a C1-20-hydrocarbyl group;R9' is a C1-20-hydrocarbyl group; Ar is a C6-12-aryl or C5-12-heteroaryl group optionally carrying one or more substituents R8; Ar' is a C6-12-aryl or C5-12-heteroaryl group optionally carrying one or more substituents R8';each R8 is a C1-20-hydrocarbyl group;each R8' is a C1-20 -hydrocarbyl group;wherein at least two of R2 and R2'; R6 and R6'; or Ar and Ar' are the same;and (ii) a cocatalyst comprising a compound of a group 13 metal, e.g. Al or boron.

Synthesis and biological evaluation of loxoprofen derivatives

Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.